Differential Activity of PARP Inhibitors in<i>BRCA1</i>- Versus<i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate Cancer

Abstract

PARP inhibitor efficacy is diminished in <i>BRCA1</i>- versus <i>BRCA2</i>-altered mCRPC. This is not due to an imbalance in germline mutations but might be related to more monoallelic mutations and/or concurrent <i>TP53</i> alterations in the <i>BRCA1</i> group.